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Abstract
Burkitt lymphoma (BL) is the most common paediatric cancer in sub-Saharan Africa (SSA). 
Anthracyline-based treatment is standard in resource-rich settings, but has not been described in 
SSA. Children ≤ 18 years of age with newly diagnosed BL were prospectively enrolled from June 
2013 to May 2015 in Malawi. Staging and supportive care were standardized, as was treatment 
with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) for six cycles. Among 73 
children with BL, median age was 9.2 years (interquartile range 7.7–11.8), 48 (66%) were male 
and two were positive for human immunodeficiency virus. Twelve (16%) had stage I/II disease, 36 
(49%) stage III and 25 (34%) stage IV. Grade 3/4 neutropenia occurred in 17 (25%), and grade 3/4 
anaemia in 29 (42%) of 69 evaluable children. Eighteen-month overall survival was 29% (95% 
confidence interval [CI] 18–41%) overall. Mortality was associated with age >9 years [hazard ratio 
[HR] 2.13, 95% CI 1.15–3.94], female gender (HR 2.12, 95% CI 1.12–4.03), stage (HR 1.52 per 
unit, 95% CI 1.07–2.17), lactate dehydrogenase (HR 1.03 per 100 iu/l, 95% CI 1.01–1.05), 
albumin (HR 0. 96 per g/l, 95% CI 0.93–0.99) and performance status (HR 0.78 per 10-point 
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increase, 95% CI 0.69–0.89). CHOP did not improve outcomes in paediatric BL compared to less 
intensive regimens in Malawi.
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INTRODUCTION
Burkitt lymphoma (BL) accounts for 50% of paediatric cancer in Malawi, with an annual 
incidence of 36 cases per 100,000 population, among the highest in sub-Saharan Africa 
(SSA) [Msyamboza et al (2012); Mwanda (2004); Sinfield et al (2007)]. For BL in resource-
rich settings, cure rates of 90% or greater are achievable using intensive chemotherapy 
regimens incorporating anthracyclines and high-dose methotrexate [Adde et al (1998); Ferry 
(2006); Magrath (2009); Magrath et al (1996); Patte et al (2001)]. However, in low-resource 
settings in SSA, there is no accepted standard for BL treatment. Cure rates using low- and 
medium-intensity chemotherapy in SSA are substantially lower, with event-free survival 
(EFS) or overall survival (OS) ranging between 25 and 62 % [Depani et al, (2015); 
Hesseling et al (2009); Hesseling et al (2006); Kazembe et al (2003); Ngoma et al (2012); 
Nkrumah and Perkins (1976); Olweny et al (1980)]. More intensive protocols incorporating 
high-dose methotrexate have often resulted in excessive treatment-related mortality given the 
supportive care limitations in this region [Harif et al (2008); Hesseling et al (2005); 
Hesseling et al (2003); Hesseling et al (2012); Stefan and Lutchman (2014); Traore et al 
(2011)]. Toxicity concerns have similarly led to anthracycline-based chemotherapy being 
infrequently applied in SSA, and the feasibility, safety and efficacy of this approach remain 
uncertain [Hesseling et al (2009); Hesseling et al (2003)]. However, CHOP 
(cyclophosphamide, doxorubicin, vincristine, prednisone) is the regional standard-of-care 
for adult non-Hodgkin lymphoma in SSA, including demonstrated safety and efficacy for 
patients with human immunodeficiency virus (HIV) [de Witt et al (2013); Gopal et al 
(2015)] and anthracycline-based approaches may be similarly applicable in children.
In this paper, we describe the clinical presentation, treatment course and toxicities, and OS 
for children with BL in Lilongwe treated with CHOP, during a period when this was the 
institutional standard for BL therapy at our centre. We also examine the risk factors 
associated with OS in a uniformly treated BL population. To our knowledge, this is the first 
prospective description of anthracycline-based chemotherapy for paediatric BL from SSA, 
and provides valuable data to guide treatment strategies for this common childhood cancer in 
the region.
METHODS
Setting
Kamuzu Central Hospital (KCH) is a national teaching hospital in the Malawian capital, 
Lilongwe. It receives cancer referrals from the northern and central regions, serving 
approximately half the total estimated population of nearly 16 million people in Malawi. 
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The paediatric cancer ward consists of 15 beds managed by two full-time clinical officers 
and two full-time nurses. The treatment protocols described were implemented after 
consultation and extensive training by paediatric haematologist-oncologists.
Patients and procedures
The KCH Lymphoma Study is an on-going prospective cohort initiated in June 2013. 
Through active case finding across all hospital departments and referring clinics, adult and 
paediatric patients with lymphoma were eligible to participate. For these analyses, we 
focused on children less than 18 years of age with newly diagnosed BL enrolled between 1 
June 2013 and 31 May 2015.
All diagnoses were pathologically confirmed using biopsies or fine needle aspirates, 
supported by immunohistochemistry (IHC) and weekly telepathology consultation involving 
2–4 pathologists in Malawi and the United States who rendered a consensus opinion [(Gopal 
et al (2013); Gopal et al (2012)]. Specific IHC stains to support lymphoma diagnosis 
included CD3, CD20, CD30, CD45, CD138, Ki67, terminal deoxynucleotidyl transferase 
(TDT) and latency-associated nuclear antigen (LANA). Other stains, including 
synaptophysin and AE1/AE3, were used to distinguish lymphomas from neuroendocrine or 
epithelial tumours, respectively, when morphology was equivocal.
At initial diagnosis, a comprehensive baseline evaluation was performed, including chest 
radiography, abdominal ultrasound, Lansky performance status [Lansky et al (1985)] and 
cerebrospinal fluid (CSF) cytology to assign Murphy stage [Murphy (1980)]. Based on 
experience with frequent relapses after less intensive therapy, institutional practice during 
the study period involved CHOP for all BL patients of any stage. Chemotherapy was 
initiated with COP prephase [cyclophosphamide 300–400 mg/m2 on day 1, vincristine 1 
mg/m2 (maximum 2 mg) on day 1, and prednisone 1.5 mg/kg/day on days 1–5]. CHOP was 
started seven days later for a total of six cycles administered every 21 days as tolerated.
Chemotherapy toxicities were graded using National Cancer Institute criteria [NCI (2009)].
[http://evs.nci.nih.gov/ftp1/CTCAE/
CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.]. Transportation reimbursement 
was provided to all paediatric oncology patients to promote retention throughout care. 
Medicines were freely provided through external funding specifically designed to mitigate 
treatment interruptions.
Analysis
Baseline characteristics are summarized using numbers with percentages or medians with 
interquartile ranges (IQRs). OS was estimated using Kaplan-Meier methods, and survival 
differences between groups were compared using the non-parametric log-rank test. We 
focused our analyses on OS as the most reliable clinical endpoint in our setting, particularly 
given that BL is a highly curable cancer for which relapse is uncommon after 12 months. We 
additionally chose OS as a more valid outcome given non-standardized criteria for response 
assessment throughout SSA, and a patient population with frequent abdominal disease that 
was evaluated serially using relatively crude methods incorporating physical examination 
and ultrasound. However, to provide more detailed data regarding cause of death, all deaths 
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in our study were separately adjudicated through consensus-centralized review involving 
multiple study investigators. Risk factors for mortality were assessed using unadjusted Cox 
proportional hazards models. Follow-up time was calculated from enrolment until death, loss 
to follow-up or censoring, which occurred on31 August 2015. All analyses were performed 
using STATA SE version 12.1 (Stata Corp., College Station, TX). Statistical significance was 
considered at a two-sided α-level of 0.05.
Ethical approval
The study was approved by the Biomedical Institutional Review Board of the University of 
North Carolina at Chapel Hill (study 12–2255)on 15 August 2013, the Protocol Review 
Committee of the Lineberger Comprehensive Cancer Centre and the Malawi National Health 
Sciences Research and Ethics Committee (doccentre@Malawi.net) (NHSRC 1107) on 10 
August 2013.
RESULTS
Baseline characteristics
Between 1 June 2013 and 31 May 2015, 73 of 89 eligible children (82%) with newly 
diagnosed BL were enrolled in the study and planned for CHOP treatment at KCH. Six 
families refused to participate, six families relocated after diagnosis and could not be 
reengaged in care, and four children died before they could be enrolled. Baseline 
characteristics for the final analytic population are shown in Table I. Median age was 9.2 
years (IQR 7.7–11.8), 48 (66%) were male and two were HIV-infected. Twelve (16%) 
presented with stage I/II disease, 36 (49%) stage III, and 25 (34%) stage IV. Thirty-four 
(47%) children had abdominal disease and 60 (82%) Lansky performance score ≤ 70. 
Twenty-five children (34%) were underweight, defined as weight-for-age z-score <−2 if less 
than five years of age or body mass index (BMI) z-score <−2 if older than five years of age, 
as per World Health Organization (WHO) reference tools [ http://www.who.int/childgrowth/
standards/technical_report/en/]. Fifty-five children (75%) were diagnosed by cytology and 
18 (25%) by histology or cell-block supported by IHC. Baseline leptomeningeal 
involvement was present in ten of 57 children (18%) who underwent initial staging lumbar 
puncture, which was omitted for some children during a five-month period when intrathecal 
methotrexate could not be purchased for clinical use anywhere in Malawi.
Treatment course and toxicities
As of 31 August, 2015, 40 children (55%) had completed six CHOP cycles, of whom 35 
(88%) and 5 (12%) achieved complete and partial response respectively. Thirty-three 
children failed to complete the planned number of CHOP cycles because of death (n=29), 
treatment abandonment (n=3) or disease progression (n=1). Median number of cycles per 
patient was 5 (IQR 3–6) and median number of days between cycles was 21 (IQR 20–22). 
The median cyclophosphamide dose per cycle was 720 mg/m2 (IQR 620–820 mg/m2) and 
median doxorubicin dose per cycle was 38 mg/m2 (IQR 34–44 mg/m2). CHOP was delayed 
for more than seven days in 32 (7%) of 432 total cycles, due to delayed absolute neutrophil 
recovery (ANC) recovery (n=18), social issues (n=12) and pharmacy stock-out (n=2).
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Figure 1 depicts peripheral blood counts over the course of therapy. As expected, the white 
blood cell count (WBC), ANC and absolute lymphocyte count (ALC) declined over time, 
but both median ANC and ALC remained ≥ 2 × 109/l throughout treatment. Any grade 3/4 
neutropenia occurred in 17 of 69 evaluable patients (25%), including 11 with any grade 3 
neutropenia (ANC 0.5–1 × 109/l) and six with any grade 4 neutropenia (ANC <0.5 × 109/l). 
Any grade 3/4 anaemia occurred in 29 of 69 evaluable patients (42%), including 24 with any 
grade 3 anaemia [Haemoglobin (Hb) 65–79 g/l] and five with any grade 4 anaemia (Hb <65 
g/l). There were no grade 3/4 thrombocytopenia events during treatment.
Survival
As of 31 August 2015, vital status was known for 70 children (96%) with a median follow-
up of 12.3 months (IQR 4.5–19.6) for 28 children not known to have died. This includes a 
median follow-up of 10.6 months (IQR 4.6–18.5) for 25 children known to be alive and 19.7 
months (range 18.8–24.4) for three children who were alive at their last visit but lost to 
follow-up prior to 31 August 2015. Of three children for whom vital status was not known, 
two had returned to Mozambique after coming to Malawi for care and could not 
subsequently be located. OS estimates with 95% confidence intervals (CIs) are shown in 
Table II, and Kaplan-Meier curves are shown in Figure 2. Estimated 18-month OS was 29% 
(95% CI 18–41%) for the cohort overall, including 51% (95% CI 19–76%) for stage I/II, 
28% (95% CI 13–46%) for stage III, and 17% (95% CI 3–39%) for stage IV. As shown in 
Figure 2, 18-month OS was worse for children aged more than 9 years, females, children 
with lactate dehydrogenase (LDH) more than twice the upper limit of normal, children with 
Lansky performance status <70, and children with weight or BMI for age z-score <−2.
Risk factors for mortality are shown in Table II. Mortality was associated with older age (9–
18 years) [hazard ratio (HR) 2.13, 95% CI 1.15–3.94, p=0.016], female gender (HR 2.12, 
95% CI 1.12–4.03, p=0.021), clinical stage per Murphy system unit increase (HR 1.52, 95% 
CI 1.07–2.17, p=0.019), LDH (HR 1.03 per 100 iu/l, 95% CI 1.01–1.05, p=0.003), albumin 
(HR 0.96 per g/l, 95% CI 0.93–0.99, p=0.033) and weight or BMI for age z-score <−2 (HR 
1.90, 95% CI 1.05–3.45, p=0.035). Better Lansky performance status was associated with 
decreased mortality (HR 0.78 per 10-point increase, 95% CI 0.69–0.89, p<0.001).
Assigning cause of death in Malawi is difficult, as there is no national system for death 
registration. Although we urged patients to return promptly for interim illnesses to be 
thoroughly evaluated, deaths often occurred at home or in health facilities where diagnostic 
resources were limited. However, central adjudication of deaths that occurred during the 
study period was undertaken to attribute cause of death (Supplemental Table 1). Of 45 
deaths, 33 (73%) were attributed to lymphoma-related causes and 12 (27%) to CHOP-
related complications. Of note, many CHOP-related deaths occurred among children with 
severe malnutrition. Estimated treatment-related mortality was 16% (12 of 73 children).
Epstein-Barr virus (EBV) association
In situ hybridization for EBV-encoded RNA (EBER) was available for nine patients for 
whom tumour blocks were evaluated in the United States, where BL was confirmed using 
broader immunohistochemistry panels and fluorescence in situ hybridization; six cases were 
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EBER-positive and three EBER-negative. All EBER-negative cases occurred in the older 
group (aged 9–18 years).
DISCUSSION
We describe the clinical presentation, treatment course and toxicities, and OS for children 
with BL treated with CHOP in Malawi. To our knowledge, this is the first prospective report 
of anthracycline-based therapy for this disease from SSA.
The 18-month OS for our cohort with principally advanced disease was 29% overall. While 
comparison across studies from the region is extremely difficult due to significant 
heterogeneity in regimens used, patient characteristics, patient selection, staging methods, 
outcomes analysed, outcome definitions and completeness of follow-up, survival in our 
cohort does not seem clearly better than published experience using less intensive regimens 
in SSA. This suggests that uniformly applied intensification with CHOP as per KCH 
institutional practice did not improve outcomes. Prior studies in Malawi using systemic 
cyclophosphamide, with or without systemic vincristine and with intrathecal methotrexate/
hydrocortisone produced an EFS of 45–50% [Depani et al (2015); Hesseling et al (2009)]. 
Another regimen developed by the International Network for Cancer Treatment and 
Research (INCTR) using systemic cyclophosphamide, vincristine and low-dose 
methotrexate, with intrathecal methotrexate and cytarabine resulted in an OS of 62% 
[Ngoma et al (2012)]. Based on our results, institutional guidelines at KCH have now been 
revised, such that stage I/II disease is treated with the less intensive, anthracycline-free 
COMP regimen (cyclophosphamide, vincristine, low dose methotrexate and prednisone with 
intrathecal methotrexate and hydrocortisone), as adapted from INCTR studies [Ngoma et al 
(2012)]. Our site is also now participating in the multicentre Burkitt Lymphoma Trial 
Network sponsored by the United States National Cancer Institute, which plans to test 
specific protocols for BL at African and Latin American centres. Experience across SSA 
overall suggests there may be a ceiling beyond which further intensification of cytotoxic 
therapy is not feasible, and incorporation of novel non-cytotoxic agents into frontline 
treatment for BL is needed.
Despite suboptimal outcomes, CHOP in our experience was feasible and well tolerated in 
many children, with grade 3/4 anaemia in 42% of children, and grade 3/4 neutropenia in 
25%. Many deaths appeared to be clearly disease-related on centralized review. CHOP may 
therefore be another strategy deserving further investigation, particularly for stage III/IV 
disease in SSA, as these children continue to have poor outcomes using any treatment 
approach reported to date. Safety and feasibility for CHOP could also be enhanced with 
relatively modest supportive care refinements, including resource-appropriate incorporation 
of haematopoietic growth factors, and may be particularly worth studying in environments 
where paediatric haematologist/oncologist supervision is possible throughout therapy. 
Intensive nutritional support and/or dose reduction or omission of anthracyclines may also 
be important among children with poor nutritional status, given that many treatment-related 
deaths in our cohort occurred among malnourished patients.
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Treating BL in SSA is also made difficult by imprecise baseline risk stratification, which 
relies on physical examination and limited radiographic studies. As a result, any 
chemotherapy regimen, regardless of intensity, is likely to over treat/undertreat a substantial 
proportion of children, thereby compromising rates of cure. In a uniformly treated 
population, we found elevated LDH, older age, female gender, advanced stage and impaired 
performance status to be associated with mortality. LDH is well known to be a strong 
prognostic factor for nearly all lymphoma subtypes including BL [Divine et al (2005)]. 
However, LDH is often not available and typically not reported from BL studies in SSA. In 
our cohort, LDH demonstrated a continuous association with survival that was stronger than 
for clinical stage or abdominal disease, suggesting this simple, point-of-care test can be 
extremely valuable in settings where advanced imaging or bone marrow assessment may not 
be available. It is imperative that LDH be made more widely available in BL programmes in 
SSA, and these efforts should not be delayed nor obviated by equally important 
investigations into novel biomarkers for risk stratification and response assessment.
Worse survival for older children in our study is consistent with other studies from both 
resource-rich and resource-limited regions, [Burkhardt et al (2005); Divine et al (2005); 
Patte et al (2001)] and may reflect differences in tumour biology or treatment adherence in 
the older age group. Intriguingly, in a very small number of cases tested for EBV by EBER 
in situ hybridization, one third were EBER negative, all of which were among older 
children. A transition over time from EBV-positive endemic BL to EBV-negative sporadic 
BL has been described among children in South Africa [Stefan et al (2014)]. Although this 
requires additional validation in larger numbers of patients, sporadic EBV-negative BL, 
which is known to principally occur among older children and adolescents, may also occur 
in Malawi with some frequency. Inferior outcomes for girls with paediatric non-Hodgkin 
lymphoma have also been observed in other studies, although these results require validation 
and underlying reasons for this observation remain uncertain [Burkhardt et al (2011); 
Burkhardt et al (2005)].
The strengths of our study include a detailed, prospective cohort with longitudinal follow-up 
including active tracing. Tracing of patients who missed appointments almost eliminated 
loss to follow-up, and allowed us to identify many deaths occurring at home. Short median 
follow-up times and incomplete follow-up undermine many BL studies from the region, and 
these shortcomings often lead to significantly overestimated survival in SSA [Brinkhof et al 
(2010); Egger et al (2011)]. Secondly, enrolment involved active case finding from all 
hospital departments and referral clinics. Thirdly, all diagnoses were confirmed through 
weekly telepathology consensus review involving pathologists in Malawi and the United 
States. Finally, all patients received standardized and uniform treatment according to 
institutional guidelines during the study period. Limitations include referral bias at a national 
teaching hospital, and assigning cause of death based on inference through centralized 
review of all available data, as deaths are not certified in Malawi and autopsies are not 
commonly done.
In addition to more effective chemotherapy and better baseline risk stratification, several 
additional elements can further improve outcomes. Children with BL in Lilongwe presented 
overwhelmingly with advanced disease and impaired performance status. It is critical to 
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implement community education programmes to promote earlier referral and diagnosis. 
Secondly, many families left the hospital and/or refused treatment for a period of time, 
eliminating or compromising opportunities for cure. Detailed qualitative studies to assess 
reasons for treatment abandonment in SSA must be conducted, to inform optimal strategies 
for retaining families in care throughout curative treatment. Finally, improved supportive 
care, including better availability of blood products, haematopoietic growth factors, 
antimicrobial agents and nutritional support, will also lead to better outcomes.
In conclusion, CHOP treatment among children with advanced BL in Malawi did not 
improve survival compared to less intensive protocols from SSA. We do not advocate this 
approach for all children, although it may be worth investigating further for those with 
advanced disease. Many baseline characteristics in addition to clinical stage were associated 
with survival, highlighting a need to develop better risk stratification tools that are specific to 
SSA to guide BL treatment, using locally available data, including LDH. Parallel efforts to 
promote earlier diagnosis, improve supportive care and retain families throughout the care 
continuum are also essential. Through these efforts, the care continuum will include ever 
more children experiencing long-term cure and survivorship, even in SSA.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Peripheral blood counts with interquartile ranges among CHOP-treated children with 
Burkitt lymphoma in Lilongwe, Malawi
Chemotherapy was initiated with COP pre-phase [cyclophosphamide 300–400 mg/m2 on 
day 1, vincristine 1 mg/m2 (maximum 2 mg) on day 1, and prednisone 1.5 mg/kg/day on 
days 1–5]. CHOP was started seven days later for a total of six cycles administered every 21 
days as tolerated. WBC, white blood cells
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Figure 2. Kaplan-Meier overall survival estimates among CHOP-treated children with Burkitt 
lymphoma in Lilongwe, Malawi
(A) Overall cohort with 95% confidence intervals. (B) Stratified by age. (C) Stratified by 
gender. (D) Stratified by lactate dehydrogenase. (E) Stratified by clinical stage. (F) Stratified 
by Lansky performance status.
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Table I
Baseline characteristics of CHOP-treated children with Burkitt lymphoma in Lilongwe, Malawi
Total, n 73
Male 48 (65.8)
HIV negative 71 (97.3)
Clinical stage
 Stage I/II 12 (16.4)
 Stage III 36 (49.3)
 Stage IV 25 (34.3)
Age, years, median (IQR) 9.2 (7.1–11.7)
Primary site
 Abdominal only 34 (46.6)
 Facial only 20 (27.4)
 Cervical only 2 (2.7)
 Multiple sites 15 (21.1)
 Other 2 (2.7)
Diagnostic specimen
 Cytology 55 (75.3)
 Histology 18 (24.7)
CSF involvement 10/57 (17.5)
B symptoms 67 (91.8)
Weight or BMI-for-age z-score <−2‡ 25 (34.3)
Lansky performance status ≤ 70 60 (82.2)
White blood cell count, 109/l, median (IQR) 8.6 (6.8–12.1)
Absolute neutrophil count, 109/l, median (IQR) 4.0 (2.8–6.7)
Haemoglobin, g/l, median (IQR) 102 (87–115)
Platelet count, 109/l, median (IQR) 421 (277–561)
Lactate dehydrogenase, iu/l, median (IQR)╪ 628 (366–1349)
 Lactate dehydrogenase >2x ULN 24/66 (36.4)
Albumin, g/l, median (IQR) 34 (31–39)
Values given as number (%) unless indicated otherwise. CSF, cerebrospinal fluid; ULN, upper limit of normal; IQR, interquartile range.
*CSF staging was not done during a five-month period when intrathecal methotrexate could not be purchased anywhere in Malawi.
‡Weight was used if aged <5 years and BMI if aged 5 years according to World Health Organization (WHO 2007).
╪
Laboratory upper limit of normal for children is 430 iu/l.
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Table III
Unadjusted hazard ratios for mortality among CHOP-treated children with Burkitt lymphoma in Lilongwe, 
Malawi
Variable Hazard ratio 95% CI p
Female gender 2.12 1.12 – 4.03 0.021
Age ≥ 9 years 2.13 1.15 – 3.94 0.016
Clinical stage, per Murphy system unit increase 1.52 1.07 – 2.17 0.019
Lansky performance status, per 10-point increase 0.78 0.69 – 0.89 <0.001
Haemoglobin, per g/l 0.99 0.98 – 1.01 0.352
Lactate dehydrogenase, per 100 iu/l 1.03 1.01 – 1.05 0.003
Albumin, per g/l 0.96 0.93 – 0.99 0.033
Weight or BMI for age z-score <−2 1.90 1.05 – 3.45 0.035
Abdominal involvement 1.63 0.91 – 2.93 0.101
BMI, body mass index; CI, confidence interval.
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